Clinical development of phosphatidylinositol-3 kinase pathway inhibitors

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this pathway have shown that pharmacological inhibition of PI3K in humans is feasible and overall well tolerated. Furthermore, there has already been clinical evidence of anti-tumor activity in patients with advanced cancer. The intensity and duration of PI3K inhibition required for an antitumor effect and the optimal pharmacodynamic biomarker(s) of pathway inactivation remain to be established. Preclinical and early clinical data support focusing on trials with PI3K inhibitors that are at a minimum enriched with patients with alterations in this signaling pathway. These inhibitors are likely to be more effective in combination with established and other novel molecular therapies.

Original languageEnglish (US)
Pages (from-to)189-208
Number of pages20
JournalCurrent Topics in Microbiology and Immunology
Volume347
Issue number1
DOIs
StatePublished - Dec 1 2010

Fingerprint

Phosphatidylinositol 3-Kinase
Phosphatidylinositol 3-Kinases
Neoplasms
Biomarkers
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology

Cite this

Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. / Arteaga, Carlos L.

In: Current Topics in Microbiology and Immunology, Vol. 347, No. 1, 01.12.2010, p. 189-208.

Research output: Contribution to journalArticle

@article{6aa07dc55ec74caa8986d53331a43905,
title = "Clinical development of phosphatidylinositol-3 kinase pathway inhibitors",
abstract = "The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this pathway have shown that pharmacological inhibition of PI3K in humans is feasible and overall well tolerated. Furthermore, there has already been clinical evidence of anti-tumor activity in patients with advanced cancer. The intensity and duration of PI3K inhibition required for an antitumor effect and the optimal pharmacodynamic biomarker(s) of pathway inactivation remain to be established. Preclinical and early clinical data support focusing on trials with PI3K inhibitors that are at a minimum enriched with patients with alterations in this signaling pathway. These inhibitors are likely to be more effective in combination with established and other novel molecular therapies.",
author = "Arteaga, {Carlos L.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/82-2010-54",
language = "English (US)",
volume = "347",
pages = "189--208",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Clinical development of phosphatidylinositol-3 kinase pathway inhibitors

AU - Arteaga, Carlos L.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this pathway have shown that pharmacological inhibition of PI3K in humans is feasible and overall well tolerated. Furthermore, there has already been clinical evidence of anti-tumor activity in patients with advanced cancer. The intensity and duration of PI3K inhibition required for an antitumor effect and the optimal pharmacodynamic biomarker(s) of pathway inactivation remain to be established. Preclinical and early clinical data support focusing on trials with PI3K inhibitors that are at a minimum enriched with patients with alterations in this signaling pathway. These inhibitors are likely to be more effective in combination with established and other novel molecular therapies.

AB - The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this pathway have shown that pharmacological inhibition of PI3K in humans is feasible and overall well tolerated. Furthermore, there has already been clinical evidence of anti-tumor activity in patients with advanced cancer. The intensity and duration of PI3K inhibition required for an antitumor effect and the optimal pharmacodynamic biomarker(s) of pathway inactivation remain to be established. Preclinical and early clinical data support focusing on trials with PI3K inhibitors that are at a minimum enriched with patients with alterations in this signaling pathway. These inhibitors are likely to be more effective in combination with established and other novel molecular therapies.

UR - http://www.scopus.com/inward/record.url?scp=79952109997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952109997&partnerID=8YFLogxK

U2 - 10.1007/82-2010-54

DO - 10.1007/82-2010-54

M3 - Article

VL - 347

SP - 189

EP - 208

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

IS - 1

ER -